Dr. Mohamed Ammar Katerji M.D

In 2017, the United States Food and Drug Administration (USFDA) approved the drug – Ocrevus (ocrelizumab) – as a treatment for both relapsing and progressive forms of multiple sclerosis. ...

To date, multiple sclerosis (MS), a chronic neurological condition, affects more than 2.3 million individuals worldwide. The immune system mistakenly attacks the myelin, which is the protective layer that surrounds the nerve fibers. This, in turn, disrupts the regular nerve signaling between the...

Sleep apnea is a sleep breathing disorder. It is characterized by repetitive pauses in breathing, which may occur several times per hour and may last for 10 seconds. It is usually a chronic condition. It results in poor sleep quality and excessive sleepiness in daytime. The most common type is...

Genetic mutations are responsible for a small number of Parkinson’s disease cases, but most of the cases originate from unknown environmental issues. Now scientists are turning their attention to identify the environmental risk factors that may cause Parkinson’s disease, including Helicobacter...

IntroductionA person is often regarded as when in the longitudinal course of mood disturbances, the threshold of a disorder is not met. People with bipolar disorder may spend most of their time in the state of mania, depression, or in a mixed state, while the rest are in euthymia. Certain...

Approximately 5 million individuals in the United States suffer from dementia, Alzheimer’s disease, or another type of neurological disorder. Such conditions can be expensive to treat and sadly, the financial burden falls on the patients and their families as opposed to receiving help from...